Skip to content

The Influence of Venous Tourniquet on Whole Blood Coagulation as Assessed by Thrombelastography (TEG)

Measuring the effect of using a venous tourniquet for blood sampling on whole blood coagulation as assessed by thromboelastography in healthy volunteers

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ANZCTR
Registry ID
ACTRN12609000187246
Enrollment
20
Registered
2009-04-17
Start date
2009-02-24
Completion date
Unknown
Last updated
2020-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Brief summary

Thromboelastography (TEG) is an in vitro method of measuring whole blood coagulation. It is, however, unknown whether the use of a venous tourniquet during blood sampling effects the results, making interpretation of a patients coagulation unreliable. This trial aims to answer this question.

Interventions

A single blood sample is taken from the antecubital fossa without the use of a venous tourniquet, using a 18g needle and 5 ml syringe. After a 5 minute period a second venous blood sample taken from the contralateral antecubital fossa. A venous tourniquet is use on this occasion for blood sampling. The tourniquet is applied for 30 seconds at 45mmHg prior venous puncture and released immediately after.This is also single venous puncture using a 18g needle and 5 ml syringe. This therefore forms a

A single blood sample is taken from the antecubital fossa without the use of a venous tourniquet, using a 18g needle and 5 ml syringe. After a 5 minute period a second venous blood sample taken from the contralateral antecubital fossa. A venous tourniquet is use on this occasion for blood sampling. The tourniquet is applied for 30 seconds at 45mmHg prior venous puncture and released immediately after.This is also single venous puncture using a 18g needle and 5 ml syringe. This therefore forms a crossover study.

Sponsors

Royal Perth Hospital
Lead SponsorHospital

Study design

Allocation
Non-randomised trial
Intervention model
Crossover
Primary purpose
Diagnosis
Masking
Open (masking not used)

Eligibility

Sex/Gender
All
Age
18 Years to 70 Years
Healthy volunteers
Yes

Inclusion criteria

Healthy volunteers

Exclusion criteria

1. Prescription of any antiplatelet medication 2. Confirmed coagulation disorder (pathological or drug induced) 3. Confirmed systemic Inflammatory diseases 4. known pregnancy

Outcome results

None listed

Source: ANZCTR · Data processed: Feb 4, 2026